Baxter International Inc. entered into a definitive agreement to acquire Cheetah Medical Inc. for an up-front cash consideration of $190 million.
Cheetah Medical is a Boston-based provider of noninvasive monitoring technologies for blood flow dynamics used in critical care, operating room and emergency department settings.
The deal also includes an additional $40 million payable based on clinical and commercial milestones.
Cheetah Medical's technology allows for better management of patients with sepsis, acute kidney injury and other critical conditions, as well as patients undergoing surgery. Cheetah Medical's technology will also be a foundational component of a novel platform of specialized patient monitoring technologies under development, Baxter said.
The acquisition is anticipated to close in the fourth quarter, subject to closing conditions. The deal will be immaterial to Baxter's earnings in 2019 and 2020.
